MedTrace Logo

Neuropathy and Anti-GFAP Antibodies

NCT05742087 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-02-23

No results posted yet for this study

Summary

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts.

The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

Conditions

  • Neurological Diseases or Conditions
  • Neurological Diseases Associated to Anti GFAP Antibodies

Interventions

OTHER

Clinical examination

The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.

OTHER

electroneuromyography (ENMG)

Data from the ENMGs will be extracted from the cohort and analyzed.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2022-10-01
Completion
2023-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05742087 on ClinicalTrials.gov